Pau Abrisqueta
Hospital Universitari Vall d'Hebrón · University Hospital of Vall d'Hebron
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Pau Abrisqueta as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:32 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07126236 · Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea · recruiting · Large B Cell Lymphoma · principal investigator
- Ph2NCT06544785 · Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaPETHEMA Foundation · recruiting · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · principal investigator
- Ph3NCT04178798 · Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaPETHEMA Foundation · completed · Chronic Lymphocytic Leukemia- Binet Staging System · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:32 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:32 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.N Engl J Med · 2022835 citationsRCR 63.5
- Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.J Clin Oncol · 2017341 citationsRCR 10.7
- Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.Haematologica · 2021114 citationsRCR 6.1
- Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.J Clin Oncol · 2009104 citationsRCR 2.4
- 57 citationsRCR 1.5
- Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC).Br J Haematol · 202052 citationsRCR 2.1
- Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.Clin Cancer Res · 201550 citationsRCR 1.3
- Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.Haematologica · 202450 citationsRCR 6.3
- Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.J Clin Oncol · 202543 citationsRCR 9.3
- Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results.Br J Haematol · 201242 citationsRCR 1.0